BeiGene To Become First Tri-Listed Biotech Amid Offer Price Concerns
Executive Summary
Nasdaq, Hong Kong and soon Shanghai, major Chinese firm BeiGene will be listed on three stock markets globally. But the high offer price of its imminent debut on China's STAR Market has raised concern among some investments and involved the use of a rare mechanism in the country.
You may also be interested in...
Clover, Chengda IPOs Add To $1.2bn Raised By Chinese Bioventures
The listings of two vaccine manufacturers and fundraisings by seven other biopharma ventures generate around $1.2bn in new financing for Chinese companies focusing on a broad variety of therapeutic areas and indicating continued investor interest.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Explained: How China’s Public Payer Wants To Define Innovative Drugs
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter revealed during a recent industry event. The disclosure has unnerved pharma companies, which have been hit by sharp drug price discounts that were required by the public payer in exchange for reimbursement coverage.